Starling Oncology (STLNW) Total Liabilities (2019 - 2026)

Starling Oncology (STLNW) has reported Total Liabilities for 8 consecutive years, with $203.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities rose 20.36% year-over-year to $203.1 million; the trailing twelve-month figure through Jun 2026 stood at $203.1 million (up 20.36% YoY), and the FY2025 full-year result was $180.4 million, up 6.65% from the prior year.
• Total Liabilities grew to $203.1 million in Q2 2026 per STLNW's latest filing, from $184.5 million in the prior quarter.
• Across five years, Total Liabilities topped out at $203.1 million in Q2 2026 and bottomed at $65.8 million in Q2 2022.
• Historically, Total Liabilities has averaged $151.8 million across 5 years, with a median of $157.4 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities soared 518.47% in 2022, then retreated 6.01% in 2023.
• Over 5 years, Total Liabilities stood at $138.5 million in 2022, then climbed by 9.91% to $152.2 million in 2023, then climbed by 11.11% to $169.1 million in 2024, then gained by 6.65% to $180.4 million in 2025, then advanced by 12.62% to $203.1 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $203.1 million, $184.5 million, and $180.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.